---
layout: default
title: Aluminum Chloride
description: "Aluminum Chloride 的老藥新用潛力分析。模型預測等級 L5，包含 10 個預測適應症。查看 AI 預測與臨床證據完整報告。"
parent: 僅模型預測 (L5)
nav_order: 18
evidence_level: L1
indication_count: 10
---

# Aluminum Chloride

<p style="font-size: 1.25rem; color: #666; margin-bottom: 1.5rem;">
證據等級: <strong>L5</strong> | 預測適應症: <strong>10</strong> 個
</p>

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Aluminum Chloride：從止汗劑到皮膚疾病的潛在擴展

## 一句話總結

<p class="key-answer" data-question="Aluminum Chloride 可以用於治療什麼新適應症？">
Aluminum chloride 主要用作止汗劑和牙科止血劑，TxGNN 預測其可能對脂漏性角化症、脂漏性皮膚炎及多汗症相關皮膚病有治療潛力。
</p>


## 快速總覽

| 項目 | 內容 |
|------|------|
| 原適應症 | 抗多汗、牙齦止血、牙齦收斂 |
| 預測新適應症 | 脂漏性角化症、脂漏性皮膚炎、痤瘡、皮膚疾病（多汗相關） |
| TxGNN 預測分數 | 0.997（脂漏性角化症）、0.996（脂漏性皮膚炎） |
| 證據等級 | L3-L4（有文獻支持，多汗症治療） |
| 台灣上市 | 已上市 |
| 許可證數 | 4 張（目前有效 1 張） |
| 建議決策 | Hold |






## 預測適應症詳細分析

<details class="indication-section" open>
<summary>
<span class="indication-name">1. seborrheic keratosis</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.68%</span> <span class="primary-badge">主要分析</span>
</summary>
<div class="indication-content">

<h3>為什麼這個預測合理？</h3>

<p>Aluminum chloride 的主要作用機轉是阻塞汗腺管道並造成局部蛋白質沉澱，具有收斂和止血作用。</p>

<p><strong>預測的機轉分析：</strong></p>

<ol>
<li><strong>脂漏性角化症 / 脂漏性皮膚炎</strong>：這些預測的關聯性較弱。雖然 aluminum chloride 具有局部收斂作用，但目前沒有機轉上的明確支持顯示其對這些角化或發炎性疾病有效。</li>

<li><strong>皮膚疾病（多汗症相關）</strong>：這是 aluminum chloride 的核心適應症。文獻顯示：</li>
</ol>
<ul>
<li>20% aluminum chloride 溶液是多汗症的一線治療</li>
<li>可用於腋下、手掌、足底多汗症</li>
<li>也可用於殘肢多汗症的治療</li>

</ul>
<ol>
<li><strong>痤瘡</strong>：aluminum chloride 可能通過其收斂作用減少皮脂分泌，但這不是其主要用途。</li>
</ol>

<h3>臨床試驗</h3>

<p>目前無針對此特定適應症的臨床試驗登記。</p>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">2. congenital prothrombin deficiency</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.66%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
目前尚無針對此適應症的專門臨床研究。此為 TxGNN 模型預測結果，需進一步驗證。
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">3. seborrheic dermatitis</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.63%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
目前尚無針對此適應症的專門臨床研究。此為 TxGNN 模型預測結果，需進一步驗證。
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">4. acne (disease)</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.43%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
目前尚無針對此適應症的專門臨床研究。此為 TxGNN 模型預測結果，需進一步驗證。
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">5. vulvar inverted follicular keratosis</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.38%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
目前尚無針對此適應症的專門臨床研究。此為 TxGNN 模型預測結果，需進一步驗證。
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">6. skin disease</span>
<span class="evidence-badge evidence-L1">L1</span>
<span class="prediction-score">99.35%</span>
</summary>
<div class="indication-content">

<h3>臨床試驗（20 項）</h3>

<table>
<thead>
<tr><th>試驗編號</th><th>階段</th><th>狀態</th><th>人數</th><th>主要發現</th></tr>
</thead>
<tbody>
<tr><td><a href="https://clinicaltrials.gov/study/NCT03416348" target="_blank">NCT03416348</a></td><td>PHASE1</td><td>COMPLETED</td><td>95</td><td>Hyperhidrosis of the Residual Limb in Patients With Amputations: Developing a Tr...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT02661490" target="_blank">NCT02661490</a></td><td>PHASE2</td><td>COMPLETED</td><td>320</td><td>A Phase II, Randomized, Double-blind, Safety and Immunogenicity Trial of Norovir...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00509886" target="_blank">NCT00509886</a></td><td>NA</td><td>COMPLETED</td><td>24</td><td>Non-prescription Versus Prescription Topical Treatments Versus no Treatment in t...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT03731988" target="_blank">NCT03731988</a></td><td>PHASE4</td><td>COMPLETED</td><td>47</td><td>A Comparison of the Efficacy of Ablative Fractional Laser-assisted Photodynamic ...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT05501444" target="_blank">NCT05501444</a></td><td>NA</td><td>COMPLETED</td><td>7</td><td>Antiperspirant in the Treatment of Residual Limp Hyperhidrosis for Prosthetic Us...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT03236012" target="_blank">NCT03236012</a></td><td>PHASE1</td><td>COMPLETED</td><td>25</td><td>Hyperhidrosis of the Residual Limb in Patients With Amputations: Developing a Tr...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT02142504" target="_blank">NCT02142504</a></td><td>PHASE2</td><td>COMPLETED</td><td>454</td><td>Phase II, Randomized, Placebo-controlled, Double-blind, Safety and Immunogenicit...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT03433859" target="_blank">NCT03433859</a></td><td>PHASE3</td><td>COMPLETED</td><td>54</td><td>Prospective Multicentric Open Randomised Controlled Trial Comparing Topical Alum...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT01459393" target="_blank">NCT01459393</a></td><td>PHASE3</td><td>COMPLETED</td><td>137</td><td>Evaluation of the Formulation of 5-aminolevulinic Acid With Dimethylsulfoxide in...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT02028208" target="_blank">NCT02028208</a></td><td>PHASE2</td><td>COMPLETED</td><td>56</td><td>Clinical Evaluation of Metal Panel Allergens: Mercury, Aluminum and Palladium Do...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT06881394" target="_blank">NCT06881394</a></td><td>NA</td><td>RECRUITING</td><td>30</td><td>A Pilot, Open-Label, Single Site Study Evaluating the Safety and Efficacy of Top...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT03250533" target="_blank">NCT03250533</a></td><td>NA</td><td>UNKNOWN</td><td>52</td><td>Analysis of the Effects of Phototherapy With Light-emitting Diodes (LED) and Ele...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00429780" target="_blank">NCT00429780</a></td><td>PHASE2, PHASE3</td><td>COMPLETED</td><td>100</td><td>A Randomized, Safety, Immunogenicity &amp; Efficacy Study of Autoclaved Leishmania M...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT02639351" target="_blank">NCT02639351</a></td><td>PHASE1</td><td>COMPLETED</td><td>80</td><td>A Phase 1, Randomized, Observer-Blind, Dosage-Escalation Study to Evaluate the S...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT02248298" target="_blank">NCT02248298</a></td><td>PHASE1</td><td>COMPLETED</td><td>93</td><td>Efficacy of Ablative Fractional Laser-assisted Photodynamic Therapy With Short I...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT06800131" target="_blank">NCT06800131</a></td><td>PHASE1</td><td>NOT_YET_RECRUITING</td><td>40</td><td>A Phase I, Randomized, Open-Label, Active-Control Study to Evaluate Safety, Tole...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT04826094" target="_blank">NCT04826094</a></td><td>PHASE1</td><td>COMPLETED</td><td>143</td><td>A Randomized, Double-Blind Phase 1 Trial to Evaluate the Safety and Immunogenici...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT05876195" target="_blank">NCT05876195</a></td><td>NA</td><td>UNKNOWN</td><td>39</td><td>Varying Keyhole Limpet Haemocyanin-adjuvant Dose Combinations to Explore the Imm...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00429715" target="_blank">NCT00429715</a></td><td>PHASE2, PHASE3</td><td>COMPLETED</td><td>150</td><td>A Randomized, Safety, Immunogenicity &amp; Efficacy Study of Autoclaved Leishmania M...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT06748404" target="_blank">NCT06748404</a></td><td>PHASE2</td><td>RECRUITING</td><td>28</td><td>A Phase 2 Randomized Study of TriCalm Hydrogel® in the Treatment of Immunotherap...</td></tr>
</tbody>
</table>

<h3>相關文獻（19 篇）</h3>

<table>
<thead>
<tr><th>PMID</th><th>年份</th><th>類型</th><th>期刊</th><th>主要發現</th></tr>
</thead>
<tbody>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/30215934/" target="_blank">30215934</a></td><td>2018</td><td>Article</td><td>American family physician</td><td>Hyperhidrosis: Management Options.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/30710603/" target="_blank">30710603</a></td><td>2019</td><td>Article</td><td>Journal of the American Academ</td><td>The etiology, diagnosis, and management of hyperhidrosis: A comprehensive review...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/26649952/" target="_blank">26649952</a></td><td>2015</td><td>Article</td><td>Praxis</td><td>[Hyperhidrosis].</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/37142953/" target="_blank">37142953</a></td><td>2023</td><td>Article</td><td>BMC cancer</td><td>Efficacy of aluminum chloride in severe regorafenib-associated hand-foot skin re...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/31567135/" target="_blank">31567135</a></td><td>2020</td><td>Article</td><td>The American Journal of dermat</td><td>Aluminum Chloride-Induced Apoptosis Leads to Keratinization Arrest and Granular ...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/12030870/" target="_blank">12030870</a></td><td>2002</td><td>Article</td><td>Dermatologic surgery : officia</td><td>Skin barrier changes induced by aluminum oxide and sodium chloride microdermabra...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/15088261/" target="_blank">15088261</a></td><td>2003</td><td>Article</td><td>Seminars in neurology</td><td>Disorders of sweating.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/35029347/" target="_blank">35029347</a></td><td>2022</td><td>Article</td><td>Dermatitis : contact, atopic, </td><td>Aluminum-Allergen of the Year 2022.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/3134977/" target="_blank">3134977</a></td><td>1988</td><td>Article</td><td>British medical journal (Clini</td><td>Treating hyperhidrosis.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/12471696/" target="_blank">12471696</a></td><td>2002</td><td>Article</td><td>Current problems in dermatolog</td><td>Topical pharmacological treatment.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/37104962/" target="_blank">37104962</a></td><td>2023</td><td>Article</td><td>Biomaterials advances</td><td>Assessment of antibacterial properties and skin irritation potential of anodized...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/30640770/" target="_blank">30640770</a></td><td>2019</td><td>Article</td><td>Dermatologic surgery : officia</td><td>Topical Aluminum Chloride and Monsel&#x27;s Solution Block Toluidine Blue Staining in...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/24552408/" target="_blank">24552408</a></td><td>2013</td><td>Article</td><td>Dermatologic therapy</td><td>Update on pediatric hyperhidrosis.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/32990370/" target="_blank">32990370</a></td><td>2020</td><td>Article</td><td>Dermatologic therapy</td><td>Efficacy and tolerability of 20% aluminum sesquichlorohydrate vs 20% aluminum ch...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/27215162/" target="_blank">27215162</a></td><td>2016</td><td>Article</td><td>Clinics in podiatric medicine </td><td>Plantar Hyperhidrosis: An Overview.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/11260552/" target="_blank">11260552</a></td><td>2001</td><td>Article</td><td>Journal of the American Academ</td><td>Aquagenic palmoplantar keratoderma.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/40396355/" target="_blank">40396355</a></td><td>2025</td><td>Article</td><td>Journal of cutaneous medicine </td><td>A Comparative Study of Aluminum Chloride, Oxybutynin Chloride, and Botulinum Tox...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/36495093/" target="_blank">36495093</a></td><td>2022</td><td>Article</td><td>Journal der Deutschen Dermatol</td><td>Comparison of a novel aluminum lactate-based with an aluminum chloride-based ant...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/3771053/" target="_blank">3771053</a></td><td>1986</td><td>Article</td><td>International journal of derma</td><td>Frey&#x27;s syndrome.</td></tr>
</tbody>
</table>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">7. dry eye syndrome</span>
<span class="evidence-badge evidence-L4">L4</span>
<span class="prediction-score">99.31%</span>
</summary>
<div class="indication-content">

<h3>相關文獻（1 篇）</h3>

<table>
<thead>
<tr><th>PMID</th><th>年份</th><th>類型</th><th>期刊</th><th>主要發現</th></tr>
</thead>
<tbody>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/34942465/" target="_blank">34942465</a></td><td>2022</td><td>Article</td><td>Colloids and surfaces. B, Bioi</td><td>Formulation and development of tacrolimus-gellan gum nanoformulation for treatme...</td></tr>
</tbody>
</table>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">8. eye disease</span>
<span class="evidence-badge evidence-L3">L3</span>
<span class="prediction-score">99.29%</span>
</summary>
<div class="indication-content">

<h3>臨床試驗（1 項）</h3>

<table>
<thead>
<tr><th>試驗編號</th><th>階段</th><th>狀態</th><th>人數</th><th>主要發現</th></tr>
</thead>
<tbody>
<tr><td><a href="https://clinicaltrials.gov/study/NCT07122297" target="_blank">NCT07122297</a></td><td>NA</td><td>COMPLETED</td><td>52</td><td>Clinical Evaluation of Different Gingival Displacement Methods</td></tr>
</tbody>
</table>

<h3>相關文獻（12 篇）</h3>

<table>
<thead>
<tr><th>PMID</th><th>年份</th><th>類型</th><th>期刊</th><th>主要發現</th></tr>
</thead>
<tbody>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/34942465/" target="_blank">34942465</a></td><td>2022</td><td>Article</td><td>Colloids and surfaces. B, Bioi</td><td>Formulation and development of tacrolimus-gellan gum nanoformulation for treatme...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/37035098/" target="_blank">37035098</a></td><td>2023</td><td>Article</td><td>International journal of Alzhe</td><td>Prognosis of Biomarker of Alzheimer&#x27;s Disease in the Function of the Retina and ...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/15150681/" target="_blank">15150681</a></td><td>2004</td><td>Article</td><td>Archives of toxicology</td><td>Mitochondrial viability and apoptosis induced by aluminum, mercuric mercury and ...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/39257107/" target="_blank">39257107</a></td><td>2024</td><td>Article</td><td>Clinical laboratory</td><td>A Case of Ocular Infection with Clostridium tertium Caused by a Salute Gun Explo...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/22115621/" target="_blank">22115621</a></td><td>2012</td><td>Article</td><td>Pharmacology, biochemistry, an</td><td>Neurobehavioral toxic effects of perinatal oral exposure to aluminum on the deve...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/25090044/" target="_blank">25090044</a></td><td>2015</td><td>Article</td><td>Retina (Philadelphia, Pa.)</td><td>Imaging characteristics of intraocular foreign bodies: a comparative study of pl...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/23146184/" target="_blank">23146184</a></td><td>2012</td><td>Article</td><td>Applied spectroscopy</td><td>Evaluation of laser-induced breakdown spectroscopy (LIBS) for measurement of sil...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/37062685/" target="_blank">37062685</a></td><td>2023</td><td>Article</td><td>Wei sheng yan jiu = Journal of</td><td>[Change of drinking water quality in Shijiazhuang South-to-North Water Diversion...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/18378229/" target="_blank">18378229</a></td><td>2008</td><td>Article</td><td>Experimental eye research</td><td>Comparative efficacy of topical antihistamines in an animal model of early phase...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/5396686/" target="_blank">5396686</a></td><td>1969</td><td>Article</td><td>Oftalmologicheskii zhurnal</td><td>[Local action of basic aluminum chloride in experimental infectious conjunctivit...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/8000497/" target="_blank">8000497</a></td><td>1994</td><td>Article</td><td>Occupational and environmental</td><td>Upper airway irritation and small airways hyperreactivity due to exposure to pot...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/5516475/" target="_blank">5516475</a></td><td>1970</td><td>Article</td><td>Oftalmologicheskii zhurnal</td><td>[Preliminary results of the treatment of chronic conjunctivitis with an aqueous ...</td></tr>
</tbody>
</table>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">9. von Hippel anomaly</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.18%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
目前尚無針對此適應症的專門臨床研究。此為 TxGNN 模型預測結果，需進一步驗證。
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">10. chronic relapsing inflammatory optic neuropathy</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.16%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
目前尚無針對此適應症的專門臨床研究。此為 TxGNN 模型預測結果，需進一步驗證。
</div>

</div>
</details>


## 台灣上市資訊

| 許可證號 | 品名 | 劑型 | 核准適應症 | 狀態 |
|---------|------|------|-----------|------|
| 衛署藥製字第043123號 | 克狐止汗劑（汎生） | 外用液劑 | 抗多汗 | 有效 |
| 衛署藥輸字第009331號 | 牙齦止血液 | 牙科用液劑 | 牙齦止血 | 已註銷 |
| 衛署藥輸字第009332號 | 牙齦收縮止血劑 | 壓排線劑 | 牙齦止血 | 已註銷 |
| 內衛藥製字第009014號 | 純露糖漿 | 糖漿劑 | 緩解感冒症狀 | 已註銷 |

**目前有效許可證持有者**：臺灣汎生製藥廠股份有限公司

## 安全性考量

- **局部副作用**：
  - 皮膚刺激、燒灼感
  - 接觸性皮膚炎
  - 皮膚乾燥

- **特殊考量**：
  - 不可用於破損皮膚
  - 建議於睡前使用，待乾燥後再穿著衣物
  - 過敏體質者需小心使用
  - 2022 年被列為「年度過敏原」，需注意鋁過敏可能性

- **藥物交互作用**：無已知重要交互作用

安全性資訊請參考原廠仿單。

## 結論與下一步

**決策：Hold**

**理由：**
TxGNN 預測的新適應症（脂漏性角化症、脂漏性皮膚炎）缺乏機轉上的合理性支持。Aluminum chloride 的收斂作用與這些疾病的病理生理學關聯不明確。

然而，對於多汗症相關皮膚問題，aluminum chloride 已經是確立的一線治療選擇，這部分的預測是準確的。

**若考慮進一步探索需要：**
- 釐清脂漏性疾病預測的機轉依據
- 考量是否為「信號雜訊」而非真正的藥物-疾病關聯
- 目前資料不足以支持臨床試驗

**現有確立用途：**
- 局部多汗症一線治療
- 手術後殘肢多汗症
- 牙科局部止血（雖台灣已無相關許可證）

**不建議用於**：脂漏性角化症或脂漏性皮膚炎的治療，除非有更多機轉證據支持。


---

## 相關藥物報告

- [Scopolamine]({{ "/drugs/scopolamine/" | relative_url }}) - 證據等級 L5
- [Potassium Iodide]({{ "/drugs/potassium_iodide/" | relative_url }}) - 證據等級 L5
- [Paclitaxel]({{ "/drugs/paclitaxel/" | relative_url }}) - 證據等級 L5
- [Denosumab]({{ "/drugs/denosumab/" | relative_url }}) - 證據等級 L5
- [Butenafine]({{ "/drugs/butenafine/" | relative_url }}) - 證據等級 L5

---

{% include ai-analysis.html %}

{% include social-share.html %}

## 引用本報告

如需引用本報告，請使用以下格式：

**APA 格式：**
```
TwTxGNN. (2026). Aluminum Chloride老藥新用驗證報告. https://twtxgnn.yao.care/drugs/aluminum_chloride/
```

**BibTeX 格式：**
```bibtex
@misc{twtxgnn_aluminum_chloride,
  title = {Aluminum Chloride老藥新用驗證報告},
  author = {TwTxGNN Team},
  year = {2026},
  url = {https://twtxgnn.yao.care/drugs/aluminum_chloride/}
}
```

---

<div class="disclaimer">
<strong>免責聲明</strong><br>
本報告僅供學術研究參考，<strong>不構成醫療建議</strong>。藥物使用請遵循醫師指示，切勿自行調整用藥。任何老藥新用決策需經過完整的臨床驗證與法規審查。
<br><br>
<small>最後審核：2026-02-20 | 審核者：TwTxGNN Research Team</small>
</div>

{% include giscus.html %}
